SARS-CoV-2
Targeting various COVID variants by altering spike protein structure
Versatile antiviral nanoparticles, effective across SARS-CoV-2 variants.
First SARS-CoV-2 vaccinations immune response to new virus variants
Immunological imprinting impacts human antibody reaction to SARS-CoV-2 mutations.
MIT researchers are using new nanoparticles to improve vaccines
Zeolitic imidazolate frameworks boost SARS-CoV-2 spike protein trimer immunity via Toll-like receptor activation.
Iron deficiency from infection may trigger long COVID
Iron imbalance and inflammatory stress affect COVID-19 outcomes.
Current antiviral treatment course is inadequate for high-risk COVID-19
Molnupiravir's impact on SARS-CoV-2 response in at-risk outpatients.
SARS-CoV-2 variants: How a set of key covariates affect viral kinetics?
A prospective observational cohort study.
Breakthrough RNA mapping method by HIRI researchers
SHIFTR allows unbiased protein identification on RNA regions in live cells.
The complement system damages cells in long-term COVID
Persistent complement dysfunction in long COVID: Inflammation and blood clot risks.
Influenza immunity spurs rapid protection in new vaccine
Influenza boosts antibody power against SARS-CoV-2.
How ultraviolet light degrades coronavirus?
SARS-CoV-2 has among the largest of genomes for RNA viruses.
COVID-19 changes gene activity in olfactory mucosal cells in Alzheimer’s
Distinct immune responses after infection between AD patients and healthy individuals.
SARS-CoV-2 moves within neurons to infect the brain
Separate effects: SARS-CoV-2, neuroinvasion, and anosmia.